IN8bio's DeltEx DRI Doubles Progression-Free Survival in Glioblastoma, Published in JCO
INAB sits 19% above its 52-week low of $1.17.
Summary
IN8bio's Phase 1 data for its DeltEx DRI therapy in newly diagnosed glioblastoma was published in The Journal of Clinical Oncology, a top-tier peer-reviewed journal. The therapy doubled median progression-free survival to 16.1 months in patients receiving multiple doses, compared to 6.9 months with standard of care. Median overall survival reached 19.5 months versus a historical 14.6 months. The treatment was well tolerated with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity. This follows the ASCO 2026 presentation but adds the credibility of peer review and detailed survival benchmarks. With a market cap of only $13.6 million and a going concern warning, positive clinical validation is critical for the company's survival and partnership prospects. Additional program updates are expected later this year.
At the time of this announcement, INAB was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6M. The 52-week trading range was $1.17 to $2.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.